Literature DB >> 7787746

Acute leukemia with structural rearrangements of chromosome 3.

D E Horsman1, R D Gascoyne, M J Barnett.   

Abstract

Cytogenetic investigations have distinguished at least 3 distinct clinical-cytogenetic syndromes of hematopoietic malignancy with structural rearrangement of 3q. The majority of cases have breakpoints at both 3q21 and 3q26, frequently associated with monosomy 7, abnormal thrombopoiesis, and adverse outcome. Cases with only one of these breakpoints may have milder features of the syndrome. A subgroup with t(3q;5q) occurs in younger patients, occasionally with megakaryocytic dysplasia but rarely having thrombocytosis. The t(3;21) is encountered in secondary leukemias or after chemotherapy of myeloproliferative disorders. The genetic deregulations associated with each of these syndromes involve distinct genes on 3q. The majority of cases of acute leukemias with 3q rearrangements have a poor prognosis and do not respond to current modes of therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7787746     DOI: 10.3109/10428199509054422

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3.

Authors:  R H Reeves; D Patch; A H Sharpe; F Borriello; G J Freeman; S Edelhoff; C Disteche
Journal:  Mamm Genome       Date:  1997-08       Impact factor: 2.957

2.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

3.  A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy.

Authors:  Ayda Bennour; Ikram Tabka; Yosra Ben Youssef; Zahra Kmeira; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.